Patent application number | Description | Published |
20090111752 | Stable Formulation of Modified GLP-1 - Pharmaceutical formulations of GLP-1 compounds and methods for preparation thereof. | 04-30-2009 |
20090286716 | Soluble Pharmaceutical Compositions for Parenteral Administration Comprising a GLP-1 Peptide and an Insulin Peptide of Short Time Action for Treatment of Diabetes and Bulimia - Pharmaceutical composition for parenteral administration comprising a meal related insulin peptide and an insulinotropic peptide. | 11-19-2009 |
20100173844 | Stable Formulations of Peptides - Stable pharmaceutical composition comprising insulinotropic peptide. | 07-08-2010 |
20100234299 | STABLE FORMULATION OF MODIFIED GLP-1 - Pharmaceutical formulations of GLP-1 compounds and methods for preparation thereof. | 09-16-2010 |
20120225810 | PROPYLENE GLYCOL-CONTAINING PEPTIDE FORMULATIONS WHICH ARE OPTIMAL FOR PRODUCTION AND FOR USE IN INJECTION DEVICES - The present invention relates to pharmaceutical formulations comprising a peptide and propylene glycol, to methods of preparing such formulations, and to uses of such formulations in the treatment of diseases and conditions for which use of the peptide contained in such formulations is indicated. The present invention further relates to methods for reducing the clogging of injection devices by a peptide formulation and for reducing deposits on production equipment during production of a peptide formulation. | 09-06-2012 |
20130028907 | Stable Antibody Containing Compositions - The invention relates to stable and low viscous (<50 cP) protein containing compositions, in particular, but not exclusively stable antibody containing compositions and to the use of said stable proteins in therapy, in particular for the subcutaneous delivery of said stable protein. | 01-31-2013 |
20130136733 | Stable Multi-Dose Compositions Comprising an Antibody and a Preservative - The invention relates to stable, multi-dose liquid compositions containing proteins, in particular, but not exclusively stable antibodies, and to the use of said compositions in therapy, in particular for the subcutaneous delivery of said stable protein. | 05-30-2013 |